Terminated PHASE1 INTERVENTIONAL 1-arm NCT01906307

A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

Sponsor: La Jolla Pharmaceutical Company

Conditions Hepatorenal Syndrome Type I and Type II

Interventions LJPC-501

Updated 6 times since 2017 Last updated: Mar 1, 2016 Started: Mar 31, 2014 Primary completion: Nov 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Corporate decision

Other terminated trials from La Jolla Pharmaceutical Company

See all terminations from La Jolla Pharmaceutical Company

Listed as NCT01906307, this PHASE1 trial focuses on Hepatorenal Syndrome Type I and Type II and remains terminated or withdrawn. Sponsored by La Jolla Pharmaceutical Company, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

La Jolla Pharmaceutical Company

Data source: La Jolla Pharmaceutical Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States